Paul Matteis
Stock Analyst at Stifel
(1.21)
# 3,318
Out of 4,818 analysts
111
Total ratings
31.94%
Success rate
-14.32%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $242.16 | +42.47% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.71 | +181.45% | 2 | Mar 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reinstates: Buy | $78 | $60.11 | +29.77% | 1 | Mar 5, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $13.09 | +144.46% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $9.50 | +236.84% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $3.98 | +176.38% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $492.42 | +0.32% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $14.41 | +122.07% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $7.64 | -21.41% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.17 | +241.88% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.30 | +334.78% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $15.44 | +288.60% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $27.16 | +32.57% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $62.02 | +40.29% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $10.78 | +512.24% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $11.45 | +205.68% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $29.09 | +82.19% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $14.66 | +43.25% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $4.79 | +505.43% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $103.25 | +39.47% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $118.17 | +142.87% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.39 | +490.84% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.17 | +453.00% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.59 | +1,409.43% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.29 | +1,637.32% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $12.45 | +157.03% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.81 | +1,229.64% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.02 | +2,547.06% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $8.33 | +68.07% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.81 | +839.79% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $21.84 | +1,456.78% | 1 | Dec 21, 2016 |
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $242.16
Upside: +42.47%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.71
Upside: +181.45%
Rhythm Pharmaceuticals
Mar 5, 2025
Reinstates: Buy
Price Target: $78
Current: $60.11
Upside: +29.77%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $13.09
Upside: +144.46%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $9.50
Upside: +236.84%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $3.98
Upside: +176.38%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $492.42
Upside: +0.32%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $14.41
Upside: +122.07%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $7.64
Upside: -21.41%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.17
Upside: +241.88%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.30
Upside: +334.78%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $15.44
Upside: +288.60%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.16
Upside: +32.57%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $62.02
Upside: +40.29%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $10.78
Upside: +512.24%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $11.45
Upside: +205.68%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $29.09
Upside: +82.19%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $14.66
Upside: +43.25%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $4.79
Upside: +505.43%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $103.25
Upside: +39.47%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $118.17
Upside: +142.87%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $3.39
Upside: +490.84%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.17
Upside: +453.00%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.59
Upside: +1,409.43%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.29
Upside: +1,637.32%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $12.45
Upside: +157.03%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $1.81
Upside: +1,229.64%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.02
Upside: +2,547.06%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $8.33
Upside: +68.07%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.81
Upside: +839.79%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $21.84
Upside: +1,456.78%